CD8A and neoplasm: Mechanistically, αPD‐1 activation promotes the expansion of CD8 T cells,[25, 50] and modulation of CD11b induces a change in the immune cell population by reducing the number of immunosuppressive cells while establishing a more proinflammatory TME.[11, 16] Consistent with our data, ADH‐503 treatment does not affect the viability of tumor or stromal cells.[16] Stromal cells showed a slight increase in metabolic activity and DNA content upon immunomodulatory treatment, confirming the effective modulation of the immune cell compartment in response to ADH‐503 treatment in our 3D model.